LOS ANGELES, CA — January 7, 2026 — Leads & Copy — Turn Therapeutics Inc. (Nasdaq: TTRX) has appointed Martin Dewhurst to its Board of Directors, according to a recent announcement. Dewhurst brings over 30 years of global leadership experience in life sciences, with a focus on mergers and acquisitions.
Bradley Burnam, Chief Executive Officer of Turn Therapeutics, stated that Dewhurst’s appointment is crucial for advancing Turn Therapeutics’ M&A-focused strategy to expand its pipeline and accelerate long-term value creation. Burnam added that Dewhurst’s insights into capital allocation, portfolio expansion, and partnership development will be instrumental as the company evaluates opportunities that complement its platform and position the company for sustainable growth.
Dewhurst spent much of his career with McKinsey & Company, where he co-led the firm’s global life sciences practice. His expertise includes biopharmaceuticals, medical technology, genetics, and consumer health. He also co-founded and led the McKinsey Health Institute, a nonprofit organization focused on tackling pressing health challenges.
Dewhurst said he is honored to join Turn Therapeutics’ Board of Directors, noting the company’s differentiated platform addressing unmet needs across dermatology, wound care, and infectious disease. He looks forward to collaborating with the Board and management team to advance the company’s strategic priorities, including portfolio expansion and value-enhancing partnerships and acquisitions.
In addition to his consulting career, Dewhurst is a senior advisor to PJT Partners and an external partner to Lightrock. He also holds board positions, including Distalmotion. Dewhurst is an author and speaker at global forums, including Bloomberg New Economy, Milken Institute, Financial Times, and The Economist.
Dewhurst earned his undergraduate degree from Magdalen College, University of Oxford, and holds an MBA from INSEAD.
Turn Therapeutics is focused on developing and commercializing products for dermatology, wound care, and infectious disease. The company has received three FDA clearances for its wound and dermatology formulations and is advancing clinical programs in eczema and onychomycosis. Turn is also pursuing global health initiatives in thermostable vaccine delivery.
Sasha Damouni
Corporate Communications
pr@turntherapeutics.com
Source: Turn Therapeutics Inc.
